Study to Evaluate the Safety, Tolerability, and Activity of CM-101 in Patients With Systemic Sclerosis

NCT06210945 · clinicaltrials.gov ↗

PHASE2

Phase

SUSPENDED

Status

45

Enrollment

INDUSTRY

Sponsor class

Stopped pending financial resources

Conditions

Systemic Sclerosis

Interventions

DRUG: 10 mg/kg CM-101
DRUG: Placebo

Sponsor

ChemomAb Ltd.